Medtronic (MDT) Receives a Hold from Leerink Partners

In a report issued on June 3, Danielle Antalffy from Leerink Partners maintained a Hold rating on Medtronic (MDTResearch Report). The company’s shares closed last Friday at $123.85.

According to, Antalffy is a 5-star analyst with an average return of 21.7% and a 64.5% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Baxter International, and Edwards Lifesciences.

Currently, the analyst consensus on Medtronic is a Strong Buy with an average price target of $141.50.

See today’s analyst top recommended stocks >>

Medtronic’s market cap is currently $166.6B and has a P/E ratio of 46.30. The company has a Price to Book ratio of -20.01.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1949, Medtronic Plc, a medical technology company, develops, manufactures, distributes, and sells device-based medical therapies and services worldwide. It operates through four segments, including Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The company is headquartered in Dublin, Ireland.